Literature DB >> 10686449

Lipoprotein(a), other lipoproteins and hemostatic profiles in patients with ischemic stroke: the relation to cardiogenic embolism.

T Dahl1, F Kontny, C E Slagsvold, B Christophersen, U Abildgaard, O R Odegaard, L Morkrid, J Dale.   

Abstract

Lipoprotein and hemostatic profiles including coagulation inhibitors were determined in 136 patients with acute ischemic stroke. Based on clinical examination, cerebral computed tomography, Doppler ultrasonography of precerebral arteries and transthoracic echocardiography, the strokes were classified as cardioembolic (n = 38), non-cardioembolic (n = 92), and mixed cardioembolic/hypertensive (n = 6). Patients with cardioembolic stroke were older than patients with non-cardioembolic stroke. Lipoprotein(a) was higher in the cardioembolic than in the non-cardioembolic group. Lipoprotein(a) was not significantly correlated to the other lipid levels and may represent an independent lipid risk factor. The non-cardioembolic group had higher levels of total cholesterol, triglycerides, total cholesterol/high-density lipoprotein cholesterol ratio, low-density lipoprotein cholesterol, apolipoprotein A1, and apolipoprotein B. The cardioembolic group had higher concentrations of fibrinogen and D-dimer, and lower levels of antithrombin, protein C, protein S and heparin cofactor 2 than the non-cardioembolic group. The differences in the hemostatic profile are consistent with thrombosis due to activated coagulation being more involved in the pathogenesis of cardioembolic than of non-cardioembolic stroke. Lipoprotein(a) seems to be more associated with coagulation markers of thrombosis than with atherosclerosis, whereas the other lipids mainly seem to be risk factors for atherosclerosis. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10686449     DOI: 10.1159/000016039

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  6 in total

Review 1.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study.

Authors:  Bernadette Boden-Albala; Douglas E Kargman; I-Feng Lin; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Cerebrovasc Dis       Date:  2010-07-23       Impact factor: 2.762

Review 3.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

4.  Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study.

Authors:  Pankaj Arora; Rajat Kalra; Peter W Callas; Kristine S Alexander; Neil A Zakai; Virginia Wadley; Garima Arora; Brett M Kissela; Suzanne E Judd; Mary Cushman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

5.  The role of dyslipidemia and statins in venous thromboembolism.

Authors:  Joel G Ray; Frits R Rosendaal
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

6.  Low-dose statin pretreatment improves function and prognosis of recurrent ischemic stroke patients.

Authors:  Chaohua Cui; Shuju Dong; Ning Chen; Jiajia Bao; Li He
Journal:  Ther Adv Neurol Disord       Date:  2020-06-07       Impact factor: 6.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.